Factors Moving Markets- Research Report on Actavis, Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Gilead Sciences Inc. and Novo Nordisk

Fri Mar 1, 2013 8:03am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130301:nPn2285558


NEW YORK,  March 1, 2013  /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Actavis,
Inc. (NYSE: ACT), AstraZeneca PLC (NYSE: AZN), Bristol-Myers Squibb Company
(NYSE: BMY), Gilead Sciences Inc. (NASDAQ: GILD) and Novo Nordisk A/S (NYSE:
NVO). Today's readers may access these reports free of charge - including full
price targets, industry analysis and analyst ratings - via the links below.

Actavis, Inc. Research Report

The US Food and Drug Administration (FDA) recently approved Actavis' generic
Suboxone for maintenance treatment of opioid dependence. According to IMS Health
Data, total sales for Actavis Suboxone reached  $625 million  for full-year
2012, and it is expected to surge in revenues after the approval. Drug
dependence is a common problem in various regions, and Actavis' generic Suboxone
may possibly rake in a great market share in the global market. Actavis reported
net revenue increase of 13% to  $1.75 billion  during the fourth quarter and 29%
to  $5.9 billion  for full-year 2012. The Full Research Report on Actavis, Inc.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/d9b4_ACT]

--

AstraZeneca PLC Research Report

Investors are looking forward to AstraZeneca's Capital Markets Day on  March 21,
2013  when the company announces its new strategy amid the challenges caused by
global market conditions. AstraZeneca remains positive after receiving
high-level results from KODIAC-08, a 52-week-long safety trial for Naloxegol
versus usual care. The core PhaseIII programme is now completed, and AstraZeneca
is advancing Naloxegol for regulatory submission within the year. Naloxegol is
used for the treatment of opioid-pain-medicine-related constipation, and is a
product under the exclusive worldwide license agreement between AstraZeneca and
Nektar Therapeutics. The Full Research Report on AstraZeneca PLC - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/8c20_AZN]

--

Bristol-Myers Squibb Company Research Report

The collaboration agreement between Bristol-Myers and Reckitt Benckiser allows
the former to easily penetrate  Latin America  through the distribution and
marketing of several over-the-counter medicines. Bristol-Myers will receive 
$438 million  from Reckitt Benckiser apart from royalties on product sales
during its collaboration term.  Brazil  and  Mexico, both emerging markets, are
the primary segments where these several products will circulate. According to
an official press release from Bristol-Myers, the company's biopharma strategy
allows the company to focus on providing innovative medicines in areas of high
unmet medical need. The Full Research Report on Bristol-Myers Squibb Company -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/4a88_BMY  ]

--

Gilead Sciences Inc. Research Report

Despite Gilead's leadership in HIV/AIDS treatments, the company's acquisition of
YM BioSciences Inc. is a foolproof reason for analysts and investors to be
bullish about the company. The company's long-term growth looks promising as it
continues to boost its portfolio with smart acquisitions. Gilead raked in 17.6%
revenue growth to  $2.59 billion  during the fourth quarter. Analysts are
expecting Gilead to post better revenues as soon as it utilizes cancer
treatments that are reported to have a great market. The Full Research Report on
Gilead Sciences Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/5969_GILD]

--

Novo Nordisk A/S Research Report

Novo Nordisk, a global healthcare company with 90 years of innovation and
leadership in diabetes care, recently launched NovoSeven with pre-filled syringe
for fast bleeding control. NovoSeven is a support rapid treatment for
haemophilia patients with inhibitors. Novo Nordisk already received approvals
for NovoSeven from European Medicines Agency (EMA) and US Food and Drug
Administration (FDA). The company's Tresiba, a once-daily basal insulin, is also
ready for release in  Japan. Analysts are expecting Novo Nordisk to penetrate
more markets in the coming quarters. The Full Research Report on Novo Nordisk
A/S - including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.Investors-Alliance.com/r/full_research_report/4e4f_NVO]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to realize
that the ship has long sailed? You need a strong, informative community in your
arsenal. Join the group that has been consistently identifying momentous
situations as they develop - long before they become the next top news on major
financial networks.

Contact:  Patricia Byers

Email:  press@investors-alliance.com

Main: +1-(480)-745-7826


SOURCE  Investors-Alliance

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.